Clinical Trials on Peptide Receptor Radionuclide Therapy (PRRT) in Poland

Total 3 results

Erasmus Medical Center

Recruiting

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors (PRRT-PARPi)

Neuroendocrine Tumors | Peptide Receptor Radionuclide Therapy

Netherlands
Silesian Centre for Heart Diseases
Medical Research Agency, Poland

Not yet recruiting

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Heart Failure | Breast Cancer | Breast Diseases | Cardiotoxicity | Molecular Mechanisms of Pharmacological Action | Angiotensin Receptor Antagonists | Neoplasm, Breast | Cardiac Toxicity | Angiotensin II Type 1 Receptor Blockers | Cancer, Therapy-Related | Antihypertensive Agents | Sacubitril/Valsartan | Cancer...

Poland
Bayer

Active, not recruiting

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (OASIS-4)

Hot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

Spain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan

3

Subscribe